| Dr Scott Hideyuki Takahashi, PHARMD | |
|
4700 W Sunset Blvd, Department Of Pediatrics, Los Angeles, CA 90027-6082 | |
| (323) 783-1911 | |
| (323) 783-0950 |
| Full Name | Dr Scott Hideyuki Takahashi |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 4700 W Sunset Blvd, Los Angeles, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003990920 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 42737 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Scott Hideyuki Takahashi, PHARMD 4455 Boston Ave, La Crescenta, CA 91214-2452 Ph: (818) 248-4739 | Dr Scott Hideyuki Takahashi, PHARMD 4700 W Sunset Blvd, Department Of Pediatrics, Los Angeles, CA 90027-6082 Ph: (323) 783-1911 |
News Archive
Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks and global stem cell innovator, today confirmed that it has recently received additional inquiries from third parties interested in acquiring the Company.
Sensable Dental, a division of Sensable, announced the newest version of its Intellifit TE Digital Restoration System that offers dental labs even more choice, performance and flexibility in digitally designing and fabricating a wide range of dental restorations.
UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation.
› Verified 3 days ago
Robert W Cheung, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3550 S La Brea Ave, Los Angeles, CA 90016 Phone: 323-293-9397 | |
Mrs. Afaf Guirguis Karanany, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 4044 Eagle Rock Blvd, Los Angeles, CA 90065 Phone: 323-254-8642 | |
Dr. Stephanie Mary Liang Luo, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1520 San Pablo St, Los Angeles, CA 90089 Phone: 213-486-8652 | |
Mr. Benjamin S Kaster, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11340 Iowa Ave Apt 8, Los Angeles, CA 90025 Phone: 310-478-6179 Fax: 310-478-6179 | |
Sarah Kim, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11321 National Blvd, Los Angeles, CA 90064 Phone: 310-479-5729 | |
Linda Han, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6041 Cadillac Ave, Kaiser West Los Angeles Medical Center, Los Angeles, CA 90034 Phone: 323-857-3989 | |
Dr. John Ball, PHARMACIST (PHARMD) Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3400 Whittier Blvd, Los Angeles, CA 90023 Phone: 562-773-3285 Fax: 323-268-1940 |